EXHIBIT 67
[Filed Under Seal]

JPMorgan

Barclays

2007 FY Results - As Good As Could Be Expected

Neutral

477p

19 February 2008
Price Target: 570p

Banks

Carla Antunes da Silva[AC]
(44-20) 7325-8215
carla.antunes-silva@jpmorgan.com

Ashley P Stuart
(44-20) 7325 4813
ashley.p.stuart@jpmorgan.com

Price Performance



	YTD	-1M	-3M	-12M
Absolute	-8.7%	2.2%	-9.6%	-41.1%

Source: RIMES, Reuters.

Our forecast changes are detailed in Table 2, p2.

- **Barclays reported reasonably solid results** given the current backdrop. PBT was £7.1bn, slightly ahead of their consensus of £7.0bn but a touch lower than JPM estimates of £7.2bn. Basic EPS was 68.9p and DPS was 34.0p. Above all writedowns were only £1.6bn and management's tone on the conference call assuaged some of the market's concerns around this area.
- **Economic profit targets look challenging.** Barclays announced a new cumulative Economic Profit (EP) target of £9.3bn-£10.6bn between 2008E and 2011E giving a CAGR of 5-10%. As a reference Barclays reported £2.3bn in 2007. We think this looks challenging given the need to grow profits in a tough operating environment particularly when we think the level of equity backing the asset base will be increased, meaning capital charges at 10.5% of equity are likely to move up materially relative to profits. Nevertheless it does suggest that management remains considerably more bullish on the earnings outlook than most investors.
- **Remains a Neutral with a Dec 08E SOTP PT of 570p.** Although we think Barclays' risk management is probably the best of the UK banks and the business mix second to only HSBC, we also think balance sheet reduction will impinge on profitability going forwards. With investment banking also in the doldrums, material earnings growth is likely to be hard to come by. Key risks to our estimates are the possibility of further significant writedowns at BarCap and declining asset quality in UK banking.

Barclays Plc (BARC.L;BARC LN)

	2007A	2008E *(Old)*	2008E *(New)*	2009E *(Old)*	2009E *(New)*
Adj. EPS FY (p)	63.54	66.57	66.55	67.35	66.47
Adj P/E FY	7.5	7.2	7.2	7.1	7.2
Headline EPS FY (p)	68.91	68.84	68.85	69.63	68.76
Headline P/E FY	6.9	6.9	6.9	6.9	6.9
Dividend (Net) FY (p)	31	32	34	32	34
NAV/Sh FY (p)	253.9	257.4	286.8	293.3	319.7
P/NAV FY	1.9	1.9	1.7	1.6	1.5
Pretax Profit Adjusted FY (£ mn)	5,813	7,201	7,086	7,407	7,215
Net Attributable Income FY (£ mn)	4,417	4,533	4,427	4,613	4,449

Source: Company data, Reuters, JPMorgan estimates.

Company Data	
Price (p)	477
Date Of Price	19 Feb 08
52-week Range (p)	794 - 396
Mkt Cap (£ bn)	31.2
Fiscal Year End	Dec
Shares O/S (mn)	6,535

Economic Capital

Barclays announced a new economic profit target of a cumulative total of £9.3bn - £10.6bn between 2008 and 2011, representing an annual growth of 5-10%. We think this looks like an extremely challenging goal, given the fact that the bank is likely to be deleveraging and therefore increasing the relative cost of its capital charge over this period, as its equity increases. We also anticipate it simultaneously reporting flat earnings. Nevertheless it does also indicate that management is probably still much more bullish than the stock market on the earnings outlook.

Using our published net income estimates out to 2010E implies that 2011 would require more than double 2010E EP as depicted in the table below.

Table 1: Barclays Economic Capital Progression

£ million

	2004	2005	2006	2007	2008E	2009E	2010E	2011E
Stated net profit	3,254	3,447	4,571	4,417	4,427	4,449	4,816	
Amortisation of acquired intangibles	6	29	83	137	137	137	137	
Profit for economic purposes	**3,260**	**3,476**	**4,654**	**4,554**	**4,564**	**4,586**	**4,953**	
Capital charge rate	9.5%	9.5%	9.5%	9.5%	10.5%	10.5%	10.5%	
Economic capital	17,800	18,150	20,500	23,800	25,700	27,900	30,300	
Capital charge	**-1,691**	**-1,724**	**-1,948**	**-2,264**	**-2,699**	**-2,930**	**-3,182**	
Economic profit	**1,569**	**1,752**	**2,707**	**2,290**	**1,865**	**1,656**	**1,771**	4,007
Growth		12%	55%	-15%	-19%	-11%	7%	
Cumulative total 2008-2011E					**1,865**	**3,521**	**5,293**	9,300

Source: JPMorgan estimates, Company data.

Changes to Estimates

Table 2: Summary of Changes to Key Estimates

	2008E	2009E	2010E
New basic EPS (p)	68.8	68.8	74.0
EPS growth (%)	-0.1%	-0.1%	7.6%
Old basic EPS (p)	68.8	69.6	75.1
% difference	0.1%	-1.2%	-1.5%
New diluted ongoing EPS (p)	**66.5**	**66.5**	**71.6**
EPS growth (%)	**4.7%**	**-0.1%**	**7.7%**
Old diluted ongoing EPS (p)	**66.6**	**67.3**	**72.7**
% difference	**-0.1%**	**-1.2%**	**-1.6%**
New normalised EPS (p)	65.3	67.4	74.3
EPS growth (%)	1.2%	3.2%	10.2%
Old normalised EPS (p)	58.7	62.7	66.1
% difference	11.2%	7.5%	12.4%
New DPS (p)	34.0	34.0	35.4
DPS growth (%)	7.1%	7.1%	7.4%
Old DPS (p)	32.0	32.1	31.9
% difference	6.2%	5.9%	10.9%

Source: JPMorgan estimates.

Carla Antunes da Silva
(44-20) 7325-8215
carla.antunes-silva@jpmorgan.com

Valuation

Our Dec 08E target price of 570p is based on our sum-of-the-parts analysis as shown in Table 3.

Table 3: Barclays 2009E SOTP

£ million, p

	Earnings	Value	Valuation basis	Value per share	P/E (x)	P/BV (X)
UK Banking	1,898	14,501		218	7.6	2.1
o.w. Retail banking	857	6,313	RoE - g/CoE - g	95	7.4	2.5
o.w. Business banking	1,041	8,188	RoE - g/CoE - g	123	7.9	1.9
Barclays Capital	1,025	11,713	RoE - g/CoE - g	176	11.4	1.0
BGI	760	10,636	PE	160	14.0	
Wealth Management	366	4,840	RoE - g/CoE - g	73	13.2	7.5
Barclaycard	502	3,554	RoE - g/CoE - g	53	7.1	1.7
International	1,051	10,023		151	9.5	2.0
Underlying core earnings	**5,601**	**55,267**		**831**	**9.9**	**2.1**
Corporate activities	-370	-1,124	PE / BV	-17	3.0	
Capital excess / shortfall	-783	-16,057	BV	-242	20.5	
Total Barclays Group	**4,449**	**38,086**		**573**	**8.6**	**2.1**
Adjusted discount factor				1.00		
Target price		**38,086**		**570**	**8.6**	**2.1**

Source: JPMorgan estimates

Risks to our rating and price target

Key risks are the possibility of further significant writedowns at BarCap and declining asset quality in UK banking. Risks to the upside are a recovery in credit markets, reducing funding costs and helping the investment banking environment and also material progress in the US roll out and domestic restructuring.

Key Points From the Conference Call

Barclays did a reasonable job at their presentation in our view and managed to fend off some of the questions on both the size of write-downs and capital.

Outlook for BarCap

Bob Diamond remained as enthusiastic as ever, playing up the opportunity to enter the top tier in the US now that other players are retrenching. He admitted H108 will remain extremely challenging and they do not believe the rest of the world can decouple from the US. They are not speculating over a US recession but more how deep and long the downturn will be. Their assumption for the time being is that it will be shorter than usual and they expect a rebound into H208.

On more specific items, the gain on their debt of £658m has not been put through to individual product lines but the £514m of amortisation has been split predominantly in interest rates, equity and emerging markets.

Writedowns taken at YE07

They did not feel the need to make a further market statement on new marks at this stage. The £24.7bn of unobservable assets have been predominantly disclosed in their breakdown of assets. Finally once the subordination, hedges and writedowns has been taken into account their CDO exposures were marked down 72%. While this sounds comforting if you are looking at an asset that is practically worthless (such as mezzanine home equity ABS) then it is important to remember that 28% of 0 is still 0.

Leverage of balance sheet

There were several questions on balance sheet leverage. Management admitted they have geared the balance sheet in the past but feel comfortable with the current level at 5.0% equity to RWAs. They expect RWA growth to slowdown materially but maintained their 5.25% core Tier 1 ratio as a target. Our view is that in the current funding environment much of the balance sheet use for revenues streams such as negative basis trades are no longer profitable, which is naturally likely to lead to a reduction in total assets.

Summary of the Results

Key divisional highlights:

- Retail net interest income was 5.8% ahead of our estimates and insurance premiums were also £72m ahead of our estimates. Costs were 5% ahead although provisions were 4% lower giving overall PBT 7% ahead of our £1,199m estimate at £1,282m.
- UK Commercial was 4% below our estimate before exceptionals. Revenues and provisions were in-line but costs were 5% higher than we had expected to give PBT of £1,371m.
- Barclays Capital was ahead driven both by fees and commissions but also by trading income. Overall the division reported £2,335m (JPM £2,240m).
- BGI was 11.2% light with revenues 2% below our estimate at £1,926m and costs 5% above our estimate at £1,192m.
- Wealth was 8% below our expectations with revenue in-line but costs 2% higher than we anticipated.
- International was light relative to our estimates with revenues in-line, costs 2% higher and provisions 20% higher, although admittedly still small in absolute terms at £252m, giving PBT of £922m (JPM £1,046m). Within this Absa was 4% below our estimates, at £684m.
- Barclaycard was 6% below our expectation at £540m (JPM £576m) with income 2% light and costs 3% higher, although on a more positive note provisions were 5% lower than we expected at £838m.

Carla Antunes da Silva
(44-20) 7325-8215
carla.antunes-silva@jpmorgan.com

Figure 1: Barclays Group P&L

£ million, p

	H1 2006	H2 2006	H1 2007	H2 2007A	H2 2007E	2005A FY	2006A FY	2007A FY	2007E FY	2008E FY	2009E FY	2010E FY	07A/06 % growth	07A/07E % growth	08E/07E % growth	09E/08E % growth	10E/09E % growth
Interest income	10,544	11,261	12,037	13,271	11,277	17,232	21,805	25,308	22,262	25,218	26,572	28,225	16.1%	13.7%	-0.4%	5.4%	6.2%
Interest expense	-6,140	-6,522	-7,448	-8,520	-6,531	-9,157	-12,662	-15,968	-12,928	-15,642	-16,482	-17,507	26.1%	23.5%	-2.0%	5.4%	6.2%
Net interest income	**4,404**	**4,739**	**4,589**	**4,751**	**4,746**	**8,075**	**9,143**	**9,610**	**9,335**	**9,576**	**10,090**	**10,718**	**5.1%**	**2.9%**	**-0.4%**	**5.4%**	**6.2%**
Net fees and commissions	3,652	3,525	3,812	3,896	3,847	5,705	7,177	7,708	7,659	8,723	9,127	9,762	7.4%	0.6%	13.2%	4.6%	7.0%
Net trading income	2,201	1,413	2,811	948	714	2,321	3,614	3,759	3,525	2,716	2,387	2,569	**4.0%**	**6.7%**	**-27.7%**	**-12.1%**	**7.6%**
Net investment income	374	588	396	820	546	858	962	1,216	942	1,160	1,159	1,186	26.4%	29.2%	-4.6%	-0.1%	2.3%
Net premiums from insurance	510	550	442	569	443	872	1,060	1,011	885	1,142	1,154	1,156	-4.6%	14.2%	13.0%	1.1%	0.2%
Other operating income	61	153	100	88	88	147	214	188	188	285	320	320	-12.1%	0.0%	51.6%	12.3%	0.0%
Total non-interest income	**6,798**	**6,229**	**7,561**	**6,321**	**5,637**	**9,903**	**13,027**	**13,882**	**13,198**	**14,027**	**14,148**	**14,993**	**6.6%**	**5.2%**	**1.0%**	**0.9%**	**6.0%**
Total income	**11,202**	**10,968**	**12,150**	**11,072**	**10,383**	**17,978**	**22,170**	**23,492**	**22,533**	**23,603**	**24,238**	**25,711**	**6.0%**	**4.3%**	**0.5%**	**2.7%**	**6.1%**
Net insurance claims/benefits	-233	-342	-248	-244	-331	-645	-575	-492	-579	-665	-670	-670	-14.4%	-15.0%	35.2%	0.7%	0.0%
Total income, net of insurance claims	**10,969**	**10,626**	**11,902**	**10,828**	**10,052**	**17,333**	**21,595**	**23,000**	**21,954**	**22,938**	**23,568**	**25,041**	**6.5%**	**4.8%**	**-0.3%**	**2.7%**	**6.3%**
Operating expenses	-6,269	-6,405	-6,847	-6,352	-5,354	-10,527	-12,674	-13,199	-12,701	-13,205	-13,460	-14,147	4.1%	3.9%	0.0%	1.9%	5.1%
Trading surplus	**4,700**	**4,221**	**5,055**	**4,476**	**4,198**	**6,806**	**8,921**	**9,801**	**9,253**	**9,733**	**10,107**	**10,894**	**9.9%**	**5.9%**	**-0.7%**	**3.8%**	**7.8%**
Provisions for bad debts	-1,057	-1,097	-959	-1,836	-1,102	-1,571	-2,154	-2,795	-2,061	-2,686	-2,933	-3,133	29.8%	35.6%	-3.9%	9.2%	6.8%
Operating Profit	**3,643**	**3,124**	**4,096**	**2,640**	**3,096**	**5,235**	**6,767**	**7,006**	**7,192**	**7,047**	**7,174**	**7,760**	**3.5%**	**-2.6%**	**0.6%**	**1.8%**	**8.2%**
Profit from JVs and associates	30	16	0	42	28	45	46	42	28	39	41	41	-8.7%	50.0%	-7.1%	5.1%	0.0%
Exceptional items	0	323	5	23		0	323	28	0	0	0	0	-91.3%				
Pre-tax profits	**3,673**	**3,463**	**4,101**	**2,705**	**3,119**	**5,280**	**7,136**	**7,076**	**7,220**	**7,086**	**7,215**	**7,802**	**-0.8%**	**-2.0%**	**0.1%**	**1.8%**	**8.1%**
Tax	-1,072	-869	-1,158	-823	-849	-1,439	-1,941	-1,981	-2,007	-1,913	-1,948	-2,106	2.1%	-1.3%	-3.4%	1.8%	8.1%
Profit after tax	**2,601**	**2,594**	**2,943**	**1,882**	**2,270**	**3,841**	**5,195**	**5,095**	**5,213**	**5,173**	**5,267**	**5,695**	**-1.9%**	**-2.3%**	**1.5%**	**1.8%**	**8.1%**
Minority interests	-294	-330	-309	-369	-336	-394	-624	-678	-645	-746	-819	-879	8.7%	5.1%	10.0%	9.7%	7.4%
Profit attributable	**2,307**	**2,264**	**2,634**	**1,513**	**1,934**	**3,447**	**4,571**	**4,417**	**4,568**	**4,427**	**4,449**	**4,816**	-3.4%	**-3.3%**	0.2%	0.5%	8.3%
DIVISIONAL PBT BREAKDOWN																	
UK Retail	612	569	651	631	548	1,027	1,181	1,282	1,199	1,111	1,174	1,241	8.6%	6.9%	-13.3%	5.6%	5.7%
UK Business Banking	653	636	712	659	708	1,428	1,289	1,371	1,420	1,389	1,426	1,470	6.4%	-3.5%	1.3%	2.7%	3.1%
Barclays Capital	1,246	970	1,660	675	580	1,272	2,216	2,335	2,240	1,742	1,405	1,489	5.4%	4.2%	-25.4%	-19.4%	6.0%
BGI	364	350	388	346	439	542	714	734	827	963	1,041	1,123	2.8%	-11.2%	31.1%	8.1%	7.9%
Barclays Wealth	110	135	173	134	162	172	245	307	335	425	501	592	25.3%	-8.3%	38.4%	18.0%	18.2%
Barclaycard	297	161	272	268	304	687	458	540	576	656	687	753	17.9%	-6.2%	21.4%	4.8%	9.6%
International	539	430	452	483	599	690	969	935	1,046	1,191	1,351	1,484	-3.5%	-10.6%	27.4%	13.4%	9.8%
Central / exceptionals	-157	221	-207	-221	-220	-532	64	-428	-422	-391	-370	-350	-768.8%	1.4%	-8.7%	-5.4%	-5.2%
Total	**3,673**	**3,463**	**4,101**	**2,975**	**3,119**	**5,280**	**7,136**	**7,076**	**7,220**	**7,086**	**7,215**	**7,802**	**-0.8%**	**-2.0%**	**0.1%**	**1.8%**	**8.1%**

Source: JPMorgan estimates, Company data.

Analyst Certification:
The research analyst(s) denoted by an "AC" on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an "AC" on the cover or within the document individually certifies, with respect to each security or issuer that the research analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers; and (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report.

Important Disclosures

- **Market Maker/ Liquidity Provider:** JPMSL and/or an affiliate is a market maker and/or liquidity provider in Barclays.
- **Lead or Co-manager:** JPMSI or its affiliates acted as lead or co-manager in a public offering of equity and/or debt securities for Barclays within the past 12 months.
- **Client of the Firm:** Barclays is or was in the past 12 months a client of JPMSI; during the past 12 months, JPMSI provided to the company investment banking services, non-investment banking securities-related service and non-securities-related services.
- **Investment Banking (past 12 months):** JPMSI or its affiliates received in the past 12 months compensation for investment banking services from Barclays.
- **Investment Banking (next 3 months):** JPMSI or its affiliates expect to receive, or intend to seek, compensation for investment banking services in the next three months from Barclays.
- **Non-Investment Banking Compensation:** JPMSI has received compensation in the past 12 months for products or services other than investment banking from Barclays. An affiliate of JPMSI has received compensation in the past 12 months for products or services other than investment banking from Barclays.
- **Broker:** An affiliate of J.P. Morgan Securities Ltd. acts as Corporate Broker to Barclays.

Barclays (BARC.L) Price Chart



Date	Rating	Share Price (p)	Price Target (p)
09-Mar-05	N	560	600
07-Feb-06	N	619	640
22-Feb-06	N	646	650
25-May-06	N	594	670
03-Aug-06	N	628	700
27-Sep-06	N	664	630
18-Dec-06	N	722	710
21-Dec-06	N	721	730
20-Feb-07	N	782	770
02-Aug-07	N	678	800
25-Sep-07	N	616	630
18-Jan-08	N	466	570

Source: Reuters and JPMorgan; price data adjusted for stock splits and dividends.
Break in coverage Jan 31, 2006 - Feb 07, 2006. This chart shows JPMorgan's continuing coverage of this stock; the current analyst may or may not have covered it over the entire period.
JPMorgan ratings: OW = Overweight, N = Neutral, UW = Underweight.

Explanation of Equity Research Ratings and Analyst(s) Coverage Universe:
JPMorgan uses the following rating system: **Overweight** [Over the next six to twelve months, we expect this stock will outperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] **Neutral** [Over the next six to twelve months, we expect this stock will perform in line with the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] **Underweight** [Over the next six to twelve months, we expect this stock will underperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] The analyst or analyst's team's coverage universe is the sector and/or country shown on the cover of each publication. See below for the specific stocks in the certifying analyst(s) coverage universe.

Coverage Universe: **Carla Antunes da Silva:** Barclays (BARC.L), HBOS (HBOS.L), HSBC Holdings plc (HSBA.L), Lloyds TSB (LLOY.L), Royal Bank of Scotland (RBS.L)

JPMorgan Equity Research Ratings Distribution, as of December 31, 2007

	Overweight (buy)	Neutral (hold)	Underweight (sell)
JPM Global Equity Research Coverage	45%	41%	14%
IB clients*	50%	51%	38%
JPMSI Equity Research Coverage	41%	47%	12%
IB clients*	71%	64%	49%

*Percentage of investment banking clients in each rating category.
For purposes only of NASD/NYSE ratings distribution rules, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category.

Valuation and Risks: Please see the most recent company-specific research report for an analysis of valuation methodology and risks on any securities recommended herein. Research is available at http://www.morganmarkets.com , or you can contact the analyst named on the front of this note or your JPMorgan representative.

Analysts' Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking.

Other Disclosures

Options related research: If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options, please contact your JPMorgan Representative or visit the OCC's website at http://www.optionsclearing.com/publications/risks/riskstoc.pdf.

Legal Entities Disclosures
U.S.: JPMSI is a member of NYSE, FINRA and SIPC. J.P. Morgan Futures Inc. is a member of the NFA. JPMorgan Chase Bank, N.A. is a member of FDIC and is authorized and regulated in the UK by the Financial Services Authority. **U.K.:** J.P. Morgan Securities Ltd. (JPMSL) is a member of the London Stock Exchange and is authorised and regulated by the Financial Services Authority. Registered in England & Wales No. 2711006. Registered Office 125 London Wall, London EC2Y 5AJ. **South Africa:** J.P. Morgan Equities Limited is a member of the Johannesburg Securities Exchange and is regulated by the FSB. **Hong Kong:** J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong. **Korea:** J.P. Morgan Securities (Far East) Ltd, Seoul branch, is regulated by the Korea Financial Supervisory Service. **Australia:** J.P. Morgan Australia Limited (ABN 52 002 888 011/AFS Licence No: 238188) is regulated by ASIC and J.P. Morgan Securities Australia Limited (ABN 61 003 245 234/AFS Licence No: 238066) is a Market Participant with the ASX and regulated by ASIC. **Taiwan:** J.P.Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. **India:** J.P. Morgan India Private Limited is a member of the National Stock Exchange of India Limited and The Stock Exchange, Mumbai and is regulated by the Securities and Exchange Board of India. **Thailand:** JPMorgan Securities (Thailand) Limited is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission. **Indonesia:** PT J.P. Morgan Securities Indonesia is a member of the Jakarta Stock Exchange and Surabaya Stock Exchange and is regulated by the BAPEPAM. **Philippines:** J.P. Morgan Securities Philippines Inc. is a member of the Philippine Stock Exchange and is regulated by the Securities and Exchange Commission. **Brazil:** Banco J.P. Morgan S.A. is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. **Mexico:** J.P. Morgan Casa de Bolsa, S.A. de C.V., J.P. Morgan Grupo Financiero is a member of the Mexican Stock Exchange and authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. **Singapore:** This material is issued and distributed in Singapore by J.P. Morgan Securities Singapore Private Limited (JPMSS) [mica (p) 207/01/2008 and Co. Reg. No.: 199405335R] which is a member of the Singapore Exchange Securities Trading Limited and is regulated by the Monetary Authority of Singapore (MAS) and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore) which is regulated by the MAS. **Malaysia:** This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-x) which is a Participating Organization of Bursa Malaysia Securities Bhd and is licensed as a dealer by the Securities Commission in Malaysia. **Pakistan:** J. P. Morgan Pakistan Broking (Pvt.) Ltd is a member of the Karachi Stock Exchange and regulated by the Securities and Exchange Commission of Pakistan.

Country and Region Specific Disclosures
U.K. and European Economic Area (EEA): Issued and approved for distribution in the U.K. and the EEA by JPMSL. Investment research issued by JPMSL has been prepared in accordance with JPMSL's Policies for Managing Conflicts of Interest in Connection with Investment Research which outline the effective organisational and administrative arrangements set up within JPMSL for the prevention and avoidance of conflicts of interest with respect to research recommendations, including information barriers, and can be found at http://www.jpmorgan.com/pdfdoc/research/ConflictManagementPolicy.pdf. This report has been issued in the U.K. only to persons of a kind described in Article 19 (5), 38, 47 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons"). This document must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is only available to relevant persons and will be engaged in only with relevant persons. In

other EEA countries, the report has been issued to persons regarded as professional investors (or equivalent) in their home jurisdiction **Germany:** This material is distributed in Germany by J.P. Morgan Securities Ltd. Frankfurt Branch and JPMorgan Chase Bank, N.A., Frankfurt Branch who are regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht. **Australia:** This material is issued and distributed by JPMSAL in Australia to "wholesale clients" only. JPMSAL does not issue or distribute this material to "retail clients." The recipient of this material must not distribute it to any third party or outside Australia without the prior written consent of JPMSAL. For the purposes of this paragraph the terms "wholesale client" and "retail client" have the meanings given to them in section 761G of the Corporations Act 2001. **Hong Kong:** The 1% ownership disclosure as of the previous month end satisfies the requirements under Paragraph 16.5(a) of the Hong Kong Code of Conduct for persons licensed by or registered with the Securities and Futures Commission. (For research published within the first ten days of the month, the disclosure may be based on the month end data from two months' prior.) J.P. Morgan Broking (Hong Kong) Limited is the liquidity provider for derivative warrants issued by J.P. Morgan International Derivatives Ltd and listed on The Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: http://www.hkex.com.hk/prod/dw/Lp.htm. **Japan:** There is a risk that a loss may occur due to a change in the price of the shares in the case of share trading, and that a loss may occur due to the exchange rate in the case of foreign share trading. In the case of share trading, JPMorgan Securities Japan Co., Ltd., will be receiving a brokerage fee and consumption tax (shouhizei) calculated by multiplying the executed price by the commission rate which was individually agreed between JPMorgan Securities Japan Co., Ltd., and the customer in advance. Financial Instruments Firms: JPMorgan Securities Japan Co., Ltd., Kanto Local Finance Bureau (kinsho) No. [82] Participating Association / Japan Securities Dealers Association, The Financial Futures Association of Japan. **Korea:** This report may have been edited or contributed to from time to time by affiliates of J.P. Morgan Securities (Far East) Ltd, Seoul branch. **Singapore:** JPMSI and/or its affiliates may have a holding in any of the securities discussed in this report; for securities where the holding is 1% or greater, the specific holding is disclosed in the Legal Disclosures section above. **India:** For private circulation only not for sale. **Pakistan:** For private circulation only not for sale. **New Zealand:** This material is issued and distributed by JPMSAL in New Zealand only to persons whose principal business is the investment of money or who, in the course of and for the purposes of their business, habitually invest money. JPMSAL does not issue or distribute this material to members of "the public" as determined in accordance with section 3 of the Securities Act 1978. The recipient of this material must not distribute it to any third party or outside New Zealand without the prior written consent of JPMSAL.

General: Additional information is available upon request. Information has been obtained from sources believed to be reliable but JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively JPMorgan) do not warrant its completeness or accuracy except with respect to any disclosures relative to JPMSI and/or its affiliates and the analyst's involvement with the issuer that is the subject of the research. All pricing is as of the close of market for the securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. JPMSI distributes in the U.S. research published by non-U.S. affiliates and accepts responsibility for its contents. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Clients should contact analysts and execute transactions through a JPMorgan subsidiary or affiliate in their home jurisdiction unless governing law permits otherwise.

"Other Disclosures" last revised February 6, 2008.

Carla Antunes da Silva
(44-20) 7325-8215
carla.antunes-silva@jpmorgan.com

All Data As Of 19-Feb-08

Q-Snapshot: Barclays PLC

Targets & Recommendations



EPS Revisions



EPS Momentum (%)



Historical Total Return (%)



Consensus Growth Outlook (%)



Quant Return Drivers (A Score >50% indicates company ranks 'above average')

Score 0% (worst) to 100% (best)	vs Country Peers	vs (regional) IBES Industry Peers
Valuations: P/E Vs Market (12mth fwd EPS)	96%	89%
Valuations: P/E Vs Sector (12mth fwd EPS)	81%	89%
Valuations: EPS Growth (forecast)	18%	32%
Momentum: 12 Month Price Momentum	20%	29%
Momentum: 1 Month Price Reversion	48%	46%
Quality: Return On Equity (forecast)	58%	75%
Quality: Earnings Risk (Variation in Consensus)	54%	81%
Earnings&Sentiment: Earnings Momentum	23%	18%
Earnings&Sentiment: Change in Recomms	27%	27%
Earnings&Sentiment: Net Revisions Fy2 EPS	9%	15%
COMPOSITE Q-SCORE (0% To 100%)**	**34%**	**44%**

JPMorgan Composite Q-Score



Regional IBES Industry Peers (Closest by Size, Consensus. ADV = Average daily value traded in US$m over the last 3 mths)

Code	Name	Country	USD MCAP	ADV	PE FY1	Q-Score**
5-HK	HSBC Holdings PLC	United Kingdom	174,094	481.31	9.2	37%
SAN-ES	Banco Santander S.A.	Spain	106,269	2024.37	8.1	93%
ISP-IT	Intesa Sanpaolo S.p.A.	Italy	83,863	525.90	10.7	51%
BNP-FR	BNP Paribas S.A.	France	77,427	636.64	7.0	61%
BBVA-ES	Banco Bilbao Vizcaya Argentaria S.A.	Spain	73,565	1146.53	7.9	92%
BARC-GB	**Barclays PLC**	**United Kingdom**	**55,424**	**711.93**	**6.7**	**44%**
DBK-DE	Deutsche Bank AG	Germany	54,247	868.68	7.6	37%
CSGN-CH	Credit Suisse Group	Switzerland	52,271	663.18	7.6	52%
GLE-FR	Societe Generale (France)	France	47,893	712.03	43.8	3%
AIB-IE	Allied Irish Banks PLC	Ireland	16,869	74.88	6.5	20%
POP-ES	Banco Popular Espanol S.A.	Spain	16,661	185.38	8.5	84%

Country Peers (Closest by Size, Consensus. ADV = average daily value traded in US$m over the last 3 mths)

Code	Name	Industry	USD MCAP	ADV	PE FY1	Q-Score**
ADV-GB	Advent Capital (Holdings) PLC	Property/Casualty Insurance	196	0.04	5.6	14%
BATS-GB	British American Tobacco PLC	Tobacco	72,061	211.41	17.2	86%
RBS-GB	Royal Bank of Scotland Group PLC	Major Banks	69,204	721.39	5.1	56%
TSCO-GB	Tesco PLC	Food Retail	61,825	277.94	16.2	36%
AZN-GB	AstraZeneca PLC	Pharmaceuticals: Major	56,137	357.35	9.1	82%
BARC-GB	**Barclays PLC**	**Major Banks**	**55,424**	**711.93**	**6.7**	**34%**
DGE-GB	Diageo PLC	Beverages: Alcoholic	53,966	231.60	17.9	83%
ULVR-GB	Unilever PLC	Food: Major Diversified	48,959	196.07	14.5	58%
HBOS-GB	HBOS PLC	Major Banks	44,816	379.10	6.0	31%
LLOY-GB	Lloyds TSB Group PLC	Financial Conglomerates	44,691	345.92	8.4	46%
STAN-GB	Standard Chartered PLC	Major Banks	42,491	264.61	16.1	49%

Source: Factset, Thomson and JPMorgan Quantitative Research. For an explanation of the Q-Snapshot, please visit http://jpmorgan.hk.acrobat.com/qsnapshot/
Q-Snapshots are a product of JPMorgan's Global Quantitative Analysis team and provide quantitative metrics summarized in an overall company 'Q-Score.'
Q-Snapshots are based on consensus data and should not be considered as having a direct relationship with the JPMorgan analysts' recommendation.
* Total number of target prices, recommendations or EPS forecasts that make up consensus. ** The Composite Q-Score is calculated by weighting and combining the 10 Quant return drivers shown. The higher the Q-Score the higher the one month expected return. On a 14 Year back-test the stocks with the highest Q-Scores have been shown (on average) to significantly outperform those stocks with the lowest Q-Scores in this universe.

Carla Antunes da Silva
(44-20) 7325-8215
carla.antunes-silva@jpmorgan.com

Barclays: Summary of Financials

Income Statement

£ in millions,year-end Dec	FY05A	FY06A	FY07E	FY08E	FY09E	FY10E
Net interest income	8,075	9,143	9,610	9,576	10,090	10,718
% YoY change	18%	13%	5%	0%	5%	6%
Non-interest income	9,031	11,967	12,871	12,885	12,993	13,837
Fees & commissions	5,705	7,177	7,708	8,723	9,127	9,762
% YoY change	18%	26%	7%	13%	5%	7%
Trading revenues	2,321	3,614	3,759	2,716	2,387	2,569
% YoY change	56%	56%	4%	-28%	-12%	8%
Other income	1,005	1,176	1,404	1,445	1,479	1,506
Total operating revenues	17,333	21,595	23,000	22,938	23,568	25,041
% YoY change	23%	25%	7%	0%	3%	6%
Admin expenses	-10,527	-12,674	-13,199	-13,205	-13,460	-14,147
% YoY change	23%	20%	4%	0%	2%	5%
Other expenses	--	--	--	--	--	--
Pre-provision operating profit	6,806	8,921	9,801	9,733	10,107	10,894
% YoY change	22%	31%	10%	-1%	4%	8%
Loan loss provisions	-1,571	-2,154	-2,795	-2,686	-2,933	-3,133
Other provisions	0	0	0	0	0	0
Other non recurrent items	0	323	28	0	0	0
Pretax profit	5,280	7,136	7,076	7,086	7,215	7,802
% YoY change	15%	35%	-1%	0%	2%	8%
Tax	-1,439	-1,941	-1,981	-1,913	-1,948	-2,106
% Tax rate	27%	27%	28%	27%	27%	27%
Minorities	-394	-624	-678	-746	-819	-879
Net Income (Reported)	3,447	4,571	4,417	4,427	4,449	4,816

Ratio Analysis

	FY05A	FY06A	FY07E	FY08E	FY09E	FY10E
Per Share Data						
EPS reported(p)	52.6	69.8	66.7	66.5	66.5	71.6
EPS Adjusted(p)	52.6	60.2	63.5	66.5	66.5	71.6
% YoY change	5%	14%	6%	5%	0%	8%
DPS(p)	26.6	31.0	34.0	34.0	34.0	35.4
% YoY change	11%	17%	10%	0%	0%	4%
Dividend yield	4.4%	4.3%	8.0%	7.1%	7.1%	7.4%
Payout ratio	47.4%	43.2%	50.2%	49.5%	49.6%	48.0%
BV per share(p)	268	303	363	395	428	465
NAV per share(p)	151	210	254	287	320	357
Shares outstanding	6,491	6,535	6,410	6,450	6,490	6,530
Return ratios	**FY05A**	**FY06A**	**FY07E**	**FY08E**	**FY09E**	**FY10E**
RoRWA	1.41%	1.61%	1.36%	1.24%	1.20%	1.23%
Pre-tax RoE	32.3%	38.3%	32.8%	29.0%	27.1%	26.9%
RoE	21.1%	24.6%	20.5%	18.1%	16.7%	16.6%
RoNAV	33.7%	38.8%	29.5%	25.5%	22.7%	21.9%
Revenues	**FY05A**	**FY06A**	**FY07E**	**FY08E**	**FY09E**	**FY10E**
NIM (NII / AIEA)	4.3%	4.6%	4.4%	4.0%	3.9%	3.9%
Non-IR / average assets	1.1%	1.2%	1.2%	1.0%	1.0%	1.0%
Total rev / average assets	2.1%	2.2%	2.1%	1.8%	1.8%	1.8%
NII / Tot revenues	46.6%	42.3%	41.8%	41.7%	42.8%	42.8%
Fees / tot revenues	32.9%	33.2%	33.5%	38.0%	38.7%	39.0%
Trading / Tot revenues	13.4%	16.7%	16.3%	11.8%	10.1%	10.3%

Balance sheet

£ in millions,year-end Dec	FY05A	FY06A	FY07E	FY08E	FY09E	FY10E
ASSETS						
Net customer loans	268,896	282,300	345,398	361,229	385,441	411,948
% YoY change	30%	5%	22%	5%	7%	7%
Loan loss reserves	3,450	3,335	3,772	4,475	5,235	5,985
Investments	96,097	114,597	193,691	202,442	210,402	221,458
Other interest earning assets	245,000	256,719	266,267	278,296	289,240	304,439
% YoY change	15%	5%	4%	5%	4%	5%
Average interest earning assets	185,814	200,894	218,149	239,489	258,079	277,013
Goodwill	6,022	6,092	7,014	7,014	7,014	7,014
Other assets	304,892	333,744	411,219	428,098	443,832	465,904
Total assets	**924,357**	**996,787**	**1,227,361**	**1,281,554**	**1,341,165**	**1,416,748**
LIABILITIES						
Customer deposits	238,684	256,754	294,987	318,586	344,073	371,599
% YoY change	23%	8%	15%	8%	8%	8%
Long term funding	103,328	111,137	120,228	124,239	128,291	134,591
Interbank funding	75,127	79,562	90,546	93,567	96,618	101,363
Average interest bearing liabs	146,988	159,861	171,850	188,541	202,978	217,719
Other liabilities	480,965	520,137	687,587	710,525	733,700	769,732
Retirement benefit liabilities	1,823	1,807	1,537	1,537	1,537	1,537
Shareholders' equity	**17,426**	**19,799**	**23,291**	**25,509**	**27,760**	**30,335**
Minorities	7,004	7,591	9,185	7,591	9,185	7,591
Total liabilities	**924,357**	**996,787**	**1,227,361**	**1,281,554**	**1,341,165**	**1,416,748**

	FY05A	FY06A	FY07E	FY08E	FY09E	FY10E
Cost ratios						
Cost / income	60.7%	58.7%	57.4%	57.6%	57.1%	56.5%
Cost / assets	1.28%	1.32%	1.19%	1.05%	1.03%	1.03%
Staff numbers	87,600	131,700	134,900	140,632	146,103	151,892
Balance Sheet Gearing	**FY05A**	**FY06A**	**FY07E**	**FY08E**	**FY09E**	**FY10E**
Loan / deposit	113%	110%	117%	113%	112%	111%
Investment / assets	10%	11%	16%	16%	16%	16%
Loan / assets	29%	28%	28%	28%	29%	29%
Customer deposits / liabilities	26%	26%	24%	25%	26%	26%
LT Debt / liabilities	11%	11%	10%	10%	10%	10%
Asset Quality / Capital	**FY05A**	**FY06A**	**FY07E**	**FY08E**	**FY09E**	**FY10E**
Loan loss reserves / loans	1.3%	1.2%	1.1%	1.2%	1.4%	1.5%
NPLs / loans	1.9%	1.8%	1.5%	2.7%	2.8%	2.8%
LLP / RWA	0.6%	0.7%	0.8%	0.7%	0.8%	0.8%
Loan loss reserves / NPLs	66.2%	64.0%	74.1%	46.4%	49.4%	51.3%
Growth in NPLs	26.6%	0.0%	-2.3%	89.5%	10.0%	10.0%
RWAs	269,148	297,833	353,476	362,402	380,973	402,990
% YoY change	23%	11%	19%	3%	5%	6%
Core Tier 1	4.2%	4.6%	4.6%	5.1%	5.4%	5.8%
Total Tier 1	7.0%	7.7%	7.6%	8.3%	8.5%	8.7%

Source: Company data, JPMorgan estimates.

EXHIBIT 68
[Filed Under Seal]

February 20, 2008

United Kingdom
Pan-European Banks

Barclays (BARC.L - 460p) 1-Overweight

Change of Earnings Forecast

In line is positive in current markets

Robert Law
(44) 20 7102 2715
rolaw@lehman.com
LBIE, London

Raul Sinha
(44) 20 7102 9136
rasinha@lehman.com
LBIE, London

Investment Conclusion

- We regard Barclays as the best risk reward investment among the major UK banks. We believe the group's business mix gives it superior growth opportunities to its domestic peers. The numbers may prompt a rally in the sector. However, we still remain negative towards UK banks due to the risks of earnings downgrades from economic slow down.

Summary

- PBT in line with expectations at group level and in principal divisions. Key divisions all show underlying growth. A positive surprise given current conditions in our view. Current year consensus also likely to be maintained. Increased EP targets established.
- BarCap relatively resilient, due to diverse revenue streams; management maintains optimism over prospects in current year.
- DPS increased 10%; management comfortable with existing capital targets. Short term positive indication for RBS.
- Valuation of capital market assets the key uncertainty.

FY Dec	2006A	2007E		2008E		2009E	
Currency STG	Actual	Old	New	Old	New	Old	New
PTP (m)	7878	7046	7076	7850	7411	8592	8631
EPS (p stated)	83.6	67.7	68.9	76.5	70.7	86.2	84.7
EPS (p adj.)	75.9	67.7	68.6	76.5	73.5	86.2	87.5
PE (adj.)	6.3	7.7	7.0	6.8	6.5	6.0	5.5
ROE (stated %)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ROE (adj. %)	39.4	30.4	29.9	29.1	27.5	31.1	30.1
Price/NAV	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Price/NAV (adj.)	2.3	2.2	1.9	1.9	1.7	1.6	1.4

Market Data

Market Cap (m)	30107
Shares Outstanding (m)	6545.0
Float (%)	100
Net Div Yield (%)	6.74
Convertible	No
Shares per ADR	N/A

Financial Summary

NAV/Share FY06	N/A
NAV(adj.)/Share FY06	N/A
Tier 1 BIS Ratio FY07 (%)	7.6
Total BIS Ratio FY07 (%)	N/A

Stock Overview



Source: DATASTREAM

Reuters	BARC.L
Bloomberg	BARC LN
ADR	40288

Performance	1M	3M	12M
Absolute %	2	-10	-41
Rel. Market %	1	-4	-36
Rel. Sector %	3	2	-13

52 Week Range 790.00 - 420.70

Stock Rating		Target Price	
New:	1-Overweight	New:	534p
Old:	1-Overweight	Old:	554p

Sector View: 1-Positive

Recommended List

We regard the Barclays results and analysts meeting as containing positives in the reported p+l, offset by the balance sheet disclosures, which could suggest the risk of further write-downs. P+L numbers were very similar to expectations and this may be taken positively, particularly compared with results taken by some international peers. Furthermore, the company has raised the DPS by 10%, is increasing its economic profit targets and appears satisfied with its capital position. However, balance sheet disclosure shows significant exposures to currently high profile capital market areas and reserving levels, which are arguably lower than some international peers and also lower than implied by secondary market levels. In addition, investors concerns over the potential for a UK slow down are unlikely to be answered in the short term. We continue to believe that Barclays offers a relatively attractive risk reward opportunity amongst the larger domestic UK banks, being relatively diversified and with some attractive assets in its business mix. We believe several of

PLEASE SEE ANALYST(S) CERTIFICATION(S) ON PAGE 5 AND IMPORTANT DISCLOSURES INCLUDING FOREIGN AFFILIATE DISCLOSURES BEGINNING ON PAGE 7

its businesses/brands offer superior growth opportunities and justify premium valuations. These include BGI, the international banking businesses, plus BarCap and Barclaycard. We would therefore prefer the shares to RBS or HBoS. However, we remain negative towards the domestic UK banks in general, given the risks of future downgrades to earnings from economic slow-down.

We viewed the Barclays results meeting was positive in terms of tone and confidence, towards asset write-downs, capital and short term earnings prospects, including at BarCap-this may provide some short term support for the stock and the sector. However, the company could not be expected to and did not add much to its statement that would support its confidence and remove the market's concerns over UK slow-down and the potential for further capital market write-downs.

We believe 2008 earnings expectations are unlikely to move after the figures. This must be regarded as positive, given the current uncertain background. We are reducing our previously above consensus PBT expectation by 5%. However, we expect consensus to be relatively unchanged. Real downside to these numbers would require a significant deterioration in UK domestic credit risk costs, which while possible, we have yet to put in our numbers for any of the UK banks.

Management has given new and modestly increased EP targets for the next four years, despite being mindful that 2008 will be 'much less benign' than recent years.

2007 numbers were broadly as expected, a relatively positive performance, given the uncertain background. All divisions showed underlying profits growth, except for ABSA, due to the fall in the local currency.

In particular, we believe management regards profits growth at BarCap as still realistic for 2008, given the diversity of the business. This is despite expectations that H1 will prove be 'extremely challenging.' Consensus expectations are currently for BarCap to be down. We are now assuming growth of 3% on the 2007 figure and this includes further write-downs of half those taken in H2 last year.

The meeting was also relatively reassuring on capital. Management indicated that it remained comfortable with their existing capital ratio targets in the medium term. However, regulators were not surprisingly erring on the side of caution on capital. The core equity Tier 1 ratio is 5.1% and the group would continue to target 5.25%. However, the overall Tier 1 ratio of 7.8% (and 7.6% on a Basel II basis) was above its target figure. The capital indications suggest dilution from capital raising is unlikely, unless the group does require major write-downs.

The DPS was raised by 10% to 34.0p and company commented that it continues to regard a 50% pay-out as appropriate and that future payments would 'broadly' match EPS growth. This is also a positive outcome, compared some negative expectations, with a similarly positive read across to RBS.

Overall credit metrics ex capital markets appear relatively stable. The stated risk tendency was only up 4%. The UK personal sector unsecured RT fell 18%; charges also continued to fall in H2, which is positive for Lloyds TSB, which we view as the most geared to this factor. By contrast, RT increased internationally (due to expansion of the loan book) in the corporate/commercial bank. However, Barclays management did sound a note of caution on the outlook for UK commercial property lending, where we view HBoS and RBS as proportionately more exposed. In addition, risk category loans (excluding CDOs) rose by £1056m in H2, compared with just £238m in H1 and the coverage of these loans fell to 49% from 57% a year ago. Maintaining the coverage would have cost £570m in profits, or 6p in EPS. Barclays commented that the deterioration was in the corporate sector, where recovery rates are expected to be higher.

Barclays robustly defended its position on the valuation of capital market assets. It argued that different banks have different types of exposures and therefore different risks/likely losses. Positions were valued at the balance sheet date. However, any further deterioration since year-end was implied to be small, as otherwise it would have had to comment. Nevertheless, the bulk of the high profile capital markets assets are based on 'unobservable inputs.' It is therefore relatively difficult for external observers to judge the valuation of these assets, which is a key judgement for the stock and its peer group.

The group has provided details of its exposures to currently high profile capital markets areas and its current valuation of these assets. We set these out in the following table:

Barclays exposures	31.12.2007	30.06.2007	Net writedowns & charges	As a percentage
	£m	£m	£m	
ABS CDO Super Senior				
High Grade	4,869	6,151		
Mezzanine	1,149	1,629		
Exposure before hedging	6,018	7,780		
Hedges	-1,347	-348		
Net ABS CDO Super senior	**4,671**	**7,432**	**-1412**	**23%**
Other exposures				
Whole loans-sub prime	3,205	2,900		
Other direct and indirect sub-prime exposures	1,832	3,146		
Total other US Sub prime	*5,037*	*6,046*		
Alt A	4,916	3,760		
Monoline insurers	1,335	140		
Commercial mortgages	12,399	8,282		
of which - Commercial real estate	11,103	7,653		
Total Other exposures	**23,687**	**18,228**	**-823**	**3%**
SIV lite liquidity facilities	152	692		
SIVs	590	925		
Leveraged finance	**7,368**	**7317**	**-188***	**2%**
Revaluation of own debt			**658**	
Total Exposures	**35,726**	**32,977**		
Total charges			**-1765**	

* Note £188m of leveraged finance charges includes £130m of unrecognised fees.

Source Co Data and Lehman Brothers estimates

The table shows the significant capital markets risks remaining in the balance sheet. The assets total £36bn at year end, net of reserving. These assets were said to include most of the £25bn in assets classified as valued at fair value and on the basis of 'unobservable inputs.'

Specifically on the subprime ABS backed super senior CDO exposure, the management indicated that including hedges and subordination the write-downs have provided for 72% loss in the underlying subprime collateral. The CMBS exposure was said to be split equally between European and US loans with an average LTV of 67%.

The size of these exposures and the adequacy of the charges against them are likely to be the principal short term uncertainty in the shares; the exposures listed above represent 100% of the group market cap. Barclays appears to have written down these assets at the low end of the range of investment banking peers. Does this reflect better underlying assets or is it a source of further potential write-downs?

Our estimates assume a further £900m of net charges are taken in Q1 this year.

Overall profit trends were much as expected, at the PBT level, on a line by line basis and in the main divisions. Given the uncertain background, we regard this as positive.

Group PBT £7.1bn was up 6% ex disposal gains and compares with consensus expectations of £7.3bn (LB £7.0bn).

All of the principal divisions increased their profits contributions, with the exception of ABSA, where local currency depreciation kept its result flat in sterling terms.

BarCap profits of £2335m were £80m ahead of our expectations. Even if this figure was struck after some significant positive and negative features, BarCap is hardly alone in that and the bottom line is that this division exceeded expectations. Revenue of £7.1bn was £3.0bn in H2 and 29% down on H1. Reported revenue was after £795m of net write-downs booked in income and net investment income of £953m, up from £573m in 2006 and £206m at the H1 stage. Net investment income is likely to include contributions from the amortization/releases of income on assets valued using 'unobservable inputs,' which rose to £514m in 2007, against £85m the previous year. However, the abnormal items could be argued to roughly cancel out, leaving the reported revenue figure as fairly representative of actual H2 income. The revenue number contained very different trends for different product lines, as for the industry as a whole and illustrates the perhaps surprising resilience of the BarCap revenue number in conditions such as H2 last year ie as long as downturns in some areas are offset by others. Not surprisingly credit and MBS/ABS were in loss and revenues even halved compared with H1 pre write-downs. However, other areas held up; this was not solely reliant on private equity gains. Rates and EMG were up strongly on H1 and equity products, commodities and currencies also produced strong contributions.

BarCap profits also benefited from aggressive cost management; the division did show the cost control it has promised in the past, if it suffers falling revenues. Operating expenses were cut by 1% for the year and were down 40% in H2 against H1. The division cost/income, costs/net revenues and comp/net revenues ratios all improved. The management of expenses was concentrated in the performance related element, which was down 20% year on year, despite a 23% increase in headcount.

Barclays is rapidly expanding its commercial banking outside the UK. IRCB ex ABSA profits of £246m were up 22% excluding business and property disposals. The bulk of this is currently generated in Spain (£207m and up 53%). However, EMG profits were also up 25% to £142m. These figures imply losses of some £100m in other areas. The division is expanding rapidly; costs rose £217m, or 26%. However, revenue also rose 27%, with loans 34% and deposits 43%. Management has indicated that the internal build out is planned to continue to 2010 at least.

UK retail banking PBT was up 9% year on year due to continued lower unsecured charges (down 12% year on year) and lower costs. Interest income growth was driven by deposits although mortgage volumes increased more significantly than previous year, with the net share at 8% as compared to gross share of 6%. Consumer lending balances continued to decline and this along with increased mortgages contributed to a decline in asset margins.

UK business banking profits were up 7% on an underlying basis but flat on a reported basis due to lower disposal and property sale gains. Impairment charges were up 15%. The management made cautionary comments on the outlook for UK commercial real estate, where Barclays is under-represented compared with some peer group banks.

Barclaycard profits increased 18% (35% excluding one-offs) due to continuing lower UK impairment charges (down 21%) and strong international growth which resulted in loan growth of 10%. The management reaffirmed their guidance for $150m in profits from the US for 2008.

BGI profits were impacted by dollar depreciation and the charges of £80m for provision of selective support for certain liquidity products managed in the US. Net new assets in the period were £42bn of which £12bn was due to inorganic growth.

Barclays financial information and forecasts

£m	FY 2006	1H 2007	FY 2007	FY 2008E	FY 2009E
Net Interest Income	9,143	4,589	9,610	10,210	11,302
Fees and commissions	7,177	3,812	7,708	8,434	9,424
Principal transactions	4,576	3,207	4,975	3,977	4,627
Other	1,274	569	1,199	2,216	2,500
Total Non-Interest Income	13,027	7,588	13,882	14,627	16,551
Total Operating Income	**22,170**	**12,177**	**23,492**	**24,837**	**27,853**
Net insurance claims	575	248	492	553	635
Net Operating Income	**21,595**	**11,929**	**23,000**	**24,284**	**27,219**
Total Operating Expenses	12,970	6,847	13,280	14,112	15,990
Profits Before Provisions	**8,625**	**5,082**	**9,720**	**10,172**	**11,229**
Bad Debt Provisions	2,154	959	2,795	2,582	2,419
Income from JV's / Associates	46	5	42	7	8
ABSA					
Pre-exceptional pre-tax profit	**6,517**	**4,128**	**6,967**	**7,597**	**8,817**
Exceptional Items	755	0	295	0	0
Goodwill amortisation	-136	0	-186	-186	-186
Profit Before Tax	**7,136**	**4,128**	**7,076**	**7,411**	**8,631**
Tax	1,941	1,158	1,981	2,075	2,287
Minorities and prefs	624	309	678	735	801
Attributable Profit	**4,571**	**2,634**	**4,417**	**4,601**	**5,543**
Ordinary Dividend	1,771	1,340	2,092	2,301	2,522
Retained Profit	2,800	1,294	2,325	2,301	3,022
Per Share data					
EPS Reported (p)	71.9	41.4	68.9	70.7	84.7
EPS - Effective (p)	**64.2**	**41.4**	**68.6**	**73.5**	**87.5**
DPS (p)	31.0	11.5	34.0	37.4	41.1
NAV / Share (tangible)	210	219	249	286	333
Divisional Breakdown					
UK Retail Banking	1,182	651	1,290	1,474	1,593
UK Business Banking	1,366	712	1,375	1,408	1,497
Total UK Banking	**2,548**	**1,363**	**2,665**	**2,882**	**3,090**
International Retail and Commercial	527	142	262	44	78
Barclaycard	475	272	568	628	694
Barclays Capital	2,229	1,660	2,389	2,468	3,079
BGI	719	388	742	825	908
Wealth Management	249	173	313	356	406
Closed Life Activities	0	0	0	0	0
Head Office and Other	-249	-207	-427	-452	-452
ABSA	774	310	750	847	1,016
PBT before non operating items	**7,272**	**4,102**	**7,262**	**7,598**	**8,818**
Non Operating Items	-136	-27	-186	-186	-186
PBT	**7,136**	**4,075**	**7,076**	**7,412**	**8,632**
All stats below this line include ABSA					
Key ratios					
Cost/Income Ratio (%)	60.1	57.4	57.7	58.1	58.7
RoE (%)	39.4	38.7	29.9	27.5	30.1
Tax Rate (%)	27.2	28.2	28.0	28.0	26.5
Pay-Out Ratio	46.1	56.0	54.4	56.9	52.4
Credit quality measures					
Provisions/Loans (%)	76.3	59.7	80.9	68.2	56.4
NPLs					
Loan Loss Reserves					
NPLs/Total Loans (%)					
Reserves/NPLs (%)					
Capital measures					
Tier 1 Ratio (%)	7.7	7.7	7.6	7.6	7.5
Shareholders' Funds (£m)	13,707	14,338	16,277	18,593	21,800
Risk Assets	297,833	318,200	353,878	387,996	439,198
Total Assets	996,787	1,158,262	1,227,361	1,345,694	1,523,276
Total Loans	282,300	321,243	345,398	378,699	428,673

Source: Company data, Lehman Brothers estimates

Analyst Certification:

I, Robert Law, hereby certify (1) that the views expressed in this research Company Note accurately reflect my personal views about any or all of the subject securities or issuers referred to in this Company Note and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Company Note.

Company Description:
Barclays is a UK-based international financial services business. It derives close to half of its earnings from the UK adn the rest from international operations within the group, notably in the US, Spain and Africa. Its business range from UK retail banking and cards, through SME banking to large corporate and debt-side investment banking. It also has a fast-growing asset management business and a private client banking business.

Important Disclosures:

Barclays (BARC.L) **460p (18-Feb-2008)** **1-Overweight / 1-Positive**

Rating and Price Target Chart:



Currency=STG

Date	Closing Price	Rating	Price Target
28-Nov-07	554.00		765.00
10-Oct-07	655.50		800.00
10-Oct-07	655.50	1 -Overweight	
23-Apr-07	733.00	RS -Rating Suspended	
21-Feb-07	780.00		857.00
10-Jan-07	754.50		876.00
29-Nov-06	687.00		890.00
04-Aug-06	635.50		709.00
12-Jun-06	601.50		694.00

Date	Closing Price	Rating	Price Target
26-May-06	611.50		697.00
22-Feb-06	664.00		714.00
11-Jan-06	626.50		686.00
30-Nov-05	590.50		720.00
08-Aug-05	582.00		623.00
27-May-05	522.00		598.00
22-May-05	543.00		603.00
21-Jan-05	585.00		689.00

FOR EXPLANATIONS OF RATINGS REFER TO THE STOCK RATING KEYS LOCATED ON THE PAGE FOLLOWING THE LAST PRICE CHART.

Lehman Brothers Inc. and/or an affiliate has received compensation for investment banking services from the subject company within the past 12 months.
Lehman Brothers Inc. and/or an affiliate trades regularly in the subject company's shares.
The subject company is or during the past 12 months has been an investment banking client of Lehman Brothers Inc. and/or an affiliate.

Valuation Methodology: Our price target assumes a PE multiple of 8x our projected 2008 EPS estimate of 73.5p, less 54p per share in additional potential credit losses, equivalent to 2% of the non-mortgage portfolio.

Risks Which May Impede the Achievement of the Price Target: Barclays is exposed to the risks of the UK retail, SME and commercial banking markets, as well as limited exposure to overseas markets including some emerging markets. It also has exposure to global bond and equity markets.

Important Disclosures Continued:

HBoS (HBOS.L) **639p (18-Feb-2008)** **3-Underweight / 1-Positive**

Rating and Price Target Chart:



Currency=STG

Date	Closing Price	Rating	Price Target
14-Dec-07	756.00		867.00
10-Oct-07	926.00		1028.00
10-Oct-07	926.00	3 -Underweight	
05-Sep-07	892.50		1046.00
05-Sep-07	892.50	1 -Overweight	
02-Aug-07	964.50		1114.00
23-Jul-07	995.00		1130.00
23-Jul-07	995.00	3 -Underweight	
13-Jun-07	1019.00		1229.00
01-Mar-07	1071.00		1240.00
01-Mar-07	1071.00	2 -Equal weight	
10-Jan-07	1156.00		1314.00

Date	Closing Price	Rating	Price Target
15-Dec-06	1114.00		1318.00
20-Sep-06	1055.00		1100.00
02-Aug-06	989.00		1134.00
22-Jun-06	934.00		1110.00
12-Jun-06	952.50		1088.00
02-Mar-06	999.00		1087.00
02-Mar-06	999.00	2 -Equal weight	
07-Dec-05	925.00		1061.00
04-Aug-05	887.00		928.00
22-Jul-05	877.00		919.00
24-Jan-05	840.00		934.00

FOR EXPLANATIONS OF RATINGS REFER TO THE STOCK RATING KEYS LOCATED ON THE PAGE FOLLOWING THE LAST PRICE CHART.

Lehman Brothers Inc. and/or an affiliate has received compensation for investment banking services from the subject company within the past 12 months.
Lehman Brothers Inc. and/or an affiliate expects to receive or intends to seek compensation for investment banking services from the subject company within the next three months.
Lehman Brothers Inc. and/or an affiliate trades regularly in the subject company's shares.
The subject company is or during the past 12 months has been an investment banking client of Lehman Brothers Inc. and/or an affiliate.

Risks Which May Impede the Achievement of the Price Target: HBoS has significant exposure to the UK mortgage market, as well as larger corporate and SME banking markets. Furthermore, it is geared to the capital markets through its life assurance businesses.

Important Disclosures Continued:

Lloyds TSB (LLOY.L) **424.5p (18-Feb-2008)** **2-Equal weight / 1-Positive**

Rating and Price Target Chart:



Currency=STG

Date	Closing Price	Rating	Price Target
11-Dec-07	498.75		613.00
23-Jul-07	568.00	2 -Equal weight	
11-Jun-07	572.00		632.00
26-Feb-07	591.50		639.00
10-Jan-07	577.50		632.00
12-Dec-06	558.00		633.00
19-Jun-06	523.50		524.00

Date	Closing Price	Rating	Price Target
27-Feb-06	565.00		512.00
11-Jan-06	505.00		477.00
13-Dec-05	480.00		478.00
01-Aug-05	488.50		416.00
21-Jun-05	476.25		442.00
07-Mar-05	504.00		471.00
21-Jan-05	471.00		465.00

FOR EXPLANATIONS OF RATINGS REFER TO THE STOCK RATING KEYS LOCATED ON THE PAGE FOLLOWING THE LAST PRICE CHART.

Lehman Brothers Inc. and /or an affiliate managed or co-managed within the past 12 months a 144A and/or public offering of securities for this company.
Lehman Brothers Inc. and/or an affiliate has received compensation for investment banking services from the subject company within the past 12 months.
Lehman Brothers Inc. and/or its affiliate beneficially owns 1% or more of any class of common equity securities of the subject company as of the end of the last month.
Lehman Brothers Inc. and/or an affiliate trades regularly in the subject company's shares.
The subject company is or during the past 12 months has been an investment banking client of Lehman Brothers Inc. and/or an affiliate.

Risks Which May Impede the Achievement of the Price Target: Lloyds TSB is exposed to the UK retail and corporate banking markets. It is also geared to capital markets and the life and general insurance industries.

Other Material Conflicts: Lehman Brothers International (Europe) acts as joint corporate broker to Lloyds TSB Group Plc.

Important Disclosures Continued:

Royal Bank Of Scotland (RBS.L) **361p (18-Feb-2008)** **3-Underweight / 1-Positive**

Rating and Price Target Chart:



Currency=STG

Date	Closing Price	Rating	Price Target	Date	Closing Price	Rating	Price Target
01-Nov-07	498.75		500.00	12-Jun-06	590.67	1 -Overweight	
01-Nov-07	498.75	3 -Underweight		01-Mar-06	644.33		656.33
01-Jun-07	632.00	RS -Rating Suspended		11-Jan-06	600.67		624.33
05-Mar-07	693.67	1 -Overweight		09-Dec-05	561.33		629.00
02-Mar-07	692.00		788.00	05-Aug-05	549.67		566.33
07-Dec-06	651.33		754.67	05-Aug-05	549.67	2 -Equal weight	
07-Aug-06	575.00		671.33	25-Feb-05	592.00		644.67
12-Jun-06	590.67		646.67	21-Jan-05	582.00		639.33

FOR EXPLANATIONS OF RATINGS REFER TO THE STOCK RATING KEYS LOCATED ON THE PAGE FOLLOWING THE LAST PRICE CHART.

Lehman Brothers Inc. and /or an affiliate managed or co-managed within the past 12 months a 144A and/or public offering of securities for this company.
Lehman Brothers Inc. and/or an affiliate has received compensation for investment banking services from the subject company within the past 12 months.
Lehman Brothers Inc. and/or an affiliate expects to receive or intends to seek compensation for investment banking services from the subject company within the next three months.
Lehman Brothers Inc. and/or its affiliate beneficially owns 1% or more of any class of common equity securities of the subject company as of the end of the last month.
Lehman Brothers Inc. and/or an affiliate trades regularly in the subject company's shares.
The subject company is or during the past 12 months has been an investment banking client of Lehman Brothers Inc. and/or an affiliate.

Risks Which May Impede the Achievement of the Price Target: RBS is a leading global commercial banking group with significant positions in personal and corporate markets. The group is exposed to deterioration in these activities, notably in credit and other areas. It has significant financial markets activities and is exposed to risks in these businesses. It has recently acquired ABN AMRO's global wholesale and international commercial banking operations. These businesses may contain unknown risks and RBS also has integration risks associated with the acquisition.

Important Disclosures Continued:
The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by investment banking activities

Company Name	Ticker	Price (18-Feb-2008)	Stock / Sector Rating
Barclays	BARC.L	460p	1-Overweight / 1-Positive

Related Stocks	Ticker	Price (18-Feb-2008)	Stock / Sector Rating
HBoS	HBOS.L	639p	3-Underweight / 1-Positive
Lloyds TSB	LLOY.L	424.5p	2-Equal weight / 1-Positive
Royal Bank Of Scotland	RBS.L	361p	3-Underweight / 1-Positive

Guide to Lehman Brothers Equity Research Rating System:
Our coverage analysts use a relative rating system in which they rate stocks as 1-Overweight, 2-Equal weight or 3-Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry sector (the "sector coverage universe"). Below is the list of companies that constitute the sector coverage universe:

ABN AMRO Holding (AAH.AS)
Allied Irish Banks (ALBK.I)
Anglo Irish Bank (ANGL.I)
Banca Popolare di Milano (PMII.MI)
Banco Popolare (BAPO.MI)
Banco Sabadell (SABE.MC)
Bank Hapoalim (POLI.TA)
Bank of Ireland (BKIR.I)
Bankinter (BKT.MC)
BBVA (BBVA.MC)
BNP Paribas (BNPP.PA)
Bradford & Bingley (BB.L)
Crédit Agricole (CAGR.PA)
Danske Bank (DANSKE.CO)
Deutsche Postbank (DPBGn.DE)
DnB NOR (DNBNOR.OL)
EFG International (EFGN.S)
Espirito Santo Financial Group (ESF.LS)
Halyk Bank (HSBKq.L)
HSBC Holdings (HSBA.L)
Intesa Sanpaolo (ISM.MI)
Julius Baer (BAER.VX)
Lloyds TSB (LLOY.L)
National Bank of Greece (NBGr.AT)
Nordea (NDA.ST)
PKO BP (PKOB.WA)
Royal Bank Of Scotland (RBS.L)
Sberbank (SBER.RTS)
SNS REAAL (SR.AS)
Standard Chartered (STAN.L)
Swedbank (SWEDa.ST)
UBS (UBSN.VX)
Van Lanschot (VLAN.AS)

Alliance & Leicester (ALLL.L)
Alpha Bank (ACBr.AT)
Banca Italease (BIL.MI)
Banco Espirito Santo (BES.LS)
Banco Popular (POP.MC)
Banesto (BTO.MC)
Bank Leumi (LUMI.TA)
Bank Pekao (BAPE.WA)
Barclays (BARC.L)
BCP (BCP.LS)
BPI (BBPI.LS)
Commerzbank (CBKG.DE)
CS Group (CSGN.VX)
Deutsche Bank (DBKGn.DE)
Dexia (DEXI.BR)
EFG Eurobank Ergasias (EFGr.AT)
Erste Bank (ERST.VI)
Fortis (FOR.AS)
HBoS (HBOS.L)
Hypo Real Estate Holding (HRXG.DE)
Israel Discount Bank (DSCT.TA)
Kazkommertsbank (KKGByq.L)
Monte dei Paschi di Siena (BMPS.MI)
Natixis (CNAT.PA)
Northern Rock (NRK.L)
Raiffeisen International Bank (RIBH.VI)
Santander (SAN.MC)
SEB (SEBa.ST)
Société Générale (SOGN.PA)
Svenska Handelsbanken (SHBa.ST)
UBI Banca (BPUN.MI)
Unicredit Group (CRDI.MI)
VTB Bank (VTBRq.L)

In addition to the stock rating, we provide sector views which rate the outlook for the sector coverage universe as 1-Positive, 2-Neutral or 3-Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.

Stock Rating
1-Overweight - The stock is expected to outperform the unweighted expected total return of the sector coverage universe over a 12-month investment horizon.
2-Equal weight - The stock is expected to perform in line with the unweighted expected total return of the sector coverage universe over a 12- month investment horizon.
3-Underweight - The stock is expected to underperform the unweighted expected total return of the sector coverage universe over a 12- month investment horizon.

RS-Rating Suspended - The rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Lehman Brothers is acting in an advisory capacity in a merger or strategic transaction involving the company.

Sector View
1-Positive - sector coverage universe fundamentals/valuations are improving.
2-Neutral - sector coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.
3-Negative - sector coverage universe fundamentals/valuations are deteriorating.

Distribution of Ratings:
Lehman Brothers Equity Research has 2173 companies under coverage.
39% have been assigned a 1-Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as Buy rating, 30% of companies with this rating are investment banking clients of the Firm.
46% have been assigned a 2-Equal weight rating which, for purposes of mandatory regulatory disclosures, is classified as Hold rating, 35% of companies with this rating are investment banking clients of the Firm.
11% have been assigned a 3-Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as Sell rating, 23% of companies with this rating are investment banking clients of the Firm.

Lehman Brothers Inc. and Its Foreign Affiliates Involved in the Production of Equity Research

New York Lehman Brothers Inc. (LBI, New York) 745 Seventh Avenue New York , New York 10019 Member, NYSE and NASD	**London** Lehman Brothers International (Europe) (LBIE, London) 25 Bank Street London, E14 5LE, United Kingdom Regulated by FSA	**Tokyo** Lehman Brothers Japan Inc. (LBJ, Tokyo) Roppongi Hills Mori Tower, 31st Floor 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan Regulated by FSA
Taipei Lehman Brothers Securities Taiwan Limited (LBSTL, Taiwan) Cathay Financial Center 12F 7 Sungren Road - Shin-Yi District Taipei, Taiwan	**Seoul** Lehman Brothers International (Europe) Seoul Branch (LBIE, Seoul) Hanwha Building, 12th Floor 110, Sokong-dong Chung-Ku Seoul 100-755, Korea Regulated by FSC	**Hong Kong** Lehman Brothers Asia Limited - Hong Kong (LBAL, Hong Kong) Two International Finance Centre 8 Finance Street, 26th Floor Central, Hong Kong Regulated by SFC
Mumbai Lehman Brothers Inc., India Branch (LBI, India) Winchester, Off High Street, 9th Floor Hiranandani Business Park, Powai, Mumbai 400 076, India	**Mumbai** Lehman Brothers Securities Private Limited (LBSPL, India) Ceejay House, 11th Level, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai 400018 Regulated by SEBI	**Sydney** Lehman Brothers Australia Securities Pty Ltd. (LBASPL, Sydney) Level 33, 264 George Street Sydney NSW 2000, Australia Regulated by ASIC

This material has been prepared and/or issued by Lehman Brothers Inc., member SIPC, and/or one of its affiliates ("Lehman Brothers") and has been approved by Lehman Brothers International (Europe), authorized and regulated by the Financial Services Authority, in connection with its distribution in the European Economic Area. This material is distributed in Japan by Lehman Brothers Japan Inc., and in Hong Kong by Lehman Brothers Asia Limited. This material is distributed in Australia by Lehman Brothers Australia Pty Limited, and in Singapore by Lehman Brothers Singapore Pte Ltd. Where this material is distributed by Lehman Brothers Singapore Pte Ltd, please note that it is intended for general circulation only and the recommendations contained herein does not take into account the specific investment objectives, financial situation or particular needs of any particular person. An investor should consult his Lehman Brothers' representative regarding the suitability of the product and take into account his specific investment objectives, financial situation or particular needs before he makes a commitment to purchase the investment product. This material is distributed in Korea by Lehman Brothers International (Europe) Seoul Branch. This document is for information purposes only and it should not be regarded as an offer to sell or as a solicitation of an offer to buy the securities or other instruments mentioned in it. No part of this document may be reproduced in any manner without the written permission of Lehman Brothers. With the exception of disclosures relating to Lehman Brothers, this research report is based on current public information that Lehman Brothers considers reliable, but we make no representation that it is accurate or complete, and it should not be relied on as such. In the case of any disclosure to the effect that Lehman Brothers Inc. or its affiliates beneficially own 1% or more of any class of common equity securities of the subject company, the computation of beneficial ownership of securities is based upon the methodology used to compute ownership under Section 13(d) of the United States' Securities Exchange Act of 1934. In the case of any disclosure to the effect that Lehman Brothers Inc. and/or its affiliates hold a short position of at least 1% of the outstanding share capital of a particular company, such disclosure relates solely to the ordinary share capital of the company. Accordingly, while such calculation represents Lehman Brothers' holdings net of any long position in the ordinary share capital of the company, such calculation excludes any rights or obligations that Lehman Brothers may otherwise have, or which may accrue in the future, with respect to such ordinary share capital. Similarly such calculation does not include any shares held or owned by Lehman Brothers where such shares are held under a wider agreement or arrangement (be it with a client or a counterparty) concerning the shares of such company (e.g. prime broking and/or stock lending activity). Any such disclosure represents the position of Lehman Brothers as of the last business day of the calendar month preceding the date of this report. This material is provided with the understanding that Lehman Brothers is not acting in a fiduciary capacity. Opinions expressed herein reflect the opinion of Lehman Brothers and are subject to change without notice. The products mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors. If an investor has any doubts about product suitability, he should consult his Lehman Brothers representative. The value of and the income produced by products may fluctuate, so that an investor may get back less than he invested. Value and income may be adversely affected by exchange rates, interest rates, or other factors. Past performance is not necessarily indicative of future results. If a product is income producing, part of the capital invested may be used to pay that income. Additional information is available on request. Please contact a Lehman Brothers entity in your home jurisdiction.

Lehman Brothers policy for managing conflicts of interest in connection with investment research is available at www.lehman.com/researchconflictspolicy. Ratings, earnings per share forecasts and price targets contained in the Firm's equity research reports covering U.S. companies are available at www.lehman.com/disclosures.

Complete disclosure information on companies covered by Lehman Brothers Equity Research is available at www.lehman.com/disclosures.

EXHIBIT 69
[Filed Under Seal]

MBIA	Primary	390	Assured Guaranty	Primary	28	FSA	Primary	83
	Trading	1402		Trading	622		Trading	2401
	Headroom	0		Headroom	149		Headroom	0
	Total	1,792		Total	799		Total	2484
AMBAC	Primary	26	Security Capital	Primary	60	CIFG	Primary	149
	Trading	1201		Trading	416		Trading	236
	Headroom	539		Headroom	11		Headroom	0
	Total	1766		Total	487		Total	385
FGIC	Primary	22	Total	Primary	758			
	Trading	282		Trading	6560			
	Headroom	807		Headroom	1506			
	Total	1111		Total	8824			

- Monolines had $2.2tn of risk positions outstanding at the end of 2006 of which 38% was structured finance. Of this c65% (c$536bn) related to US ABS and MBS (incl. CDOs). Monolines have seen very sharp falls in share prices during 2007 (e.g. AMBAC is down c75%) on speculation of downgrades and heavy losses.
- Barclays exposure to monolines is c$7.3bn (plus c$1.5bn headroom), and is largely in the form of negative basis trades (credit protection on securities held) – the notional value of these trades is c$40bn.
- Of the $40bn, c$4.1bn relates to US High Grade ($2.8bn) and US Mezz ($1.3bn) ABS CDOs.
  - Looking at the underlying asset pools on these CDOs c$3bn relates to subprime or Alt-A securities.
  - MBIA and Ambac provide the vast majority of the protection on these positions, $2.9bn and $1bn respectively.
  - Barclays owns only one $81mm CDO-squared with ABS CDO collateral in the negative basis trade book. This deal closed April 2005 and is currently marked by the underwriter at $58.3mm.
  - $2.4bn of the $4.1bn in ABS CDOs closed in 2004 or 2005. Although collateral managers may reinvest principal proceeds in more recent vintage collateral, the majority of the CDO assets are of earlier vintages and less susceptible to poor underwriting standards of 2006 and 2007
- Positions are not included in statements / analysis of subprime exposure as we principally look to the strength of the monoline in assessing the risk.
- None of the monolines shown have been downgraded, however no ratings have been reaffirmed since the latest subprime deterioration begin in early October (though Fitch reaffirmed MBIA's AAA rating on 21 September).

EXHIBIT 70
[Filed Under Seal]

[redacted] [redacted] [redacted] [redacted] [redacted] [redacted]

PAPER FOR BOARD RISK COMMITTEE MEETING ON WEDNESDAY 19 MARCH 2008

Agenda Item No.
3.1

TO: Members of the Board Risk Committee

FROM: Robert Le Blanc and Rich Ricci

DATE: 12 March 2008

SUBJECT: KEY RISK ISSUE – UPDATE ON ABS AND LEVERAGED CREDIT MARKETS

Update on ABS and Leveraged Credit Markets

Board Risk Committee

12 March 2008

BARCLAYS

Executive Summary

- The **purpose** of the paper is to provide the Board Risk Committee with a further update on Barclays exposures and market outlook for the ABS and Leveraged Credit markets.
- Net exposures as at January 2008 have been presented and they have not moved materially since year-end. Where available, February exposures have been provided. A full update for February exposures will be provided at the meeting.
- **Looking forward** there are some key risks that could significantly exacerbate the situation :
  - Further deterioration in the Alt A and commercial mortgages markets
  - Downgrade or financial stress of one of the AAA monoline insurers
  - A significant leveraged default
- The results of a severe stress test of the real estate and leveraged loan portfolio as prepared for the FSA have also been included in the presentation.

2007 results announcement summary – 19 Feb 2008

- Barclays Capital credit market exposures resulted in net losses of £1,635m in 2007, due to dislocations in the credit markets. The net losses primarily related to ABS CDO super senior exposures, with additional losses from other credit market exposures partially offset by gains from the general widening of credit spreads on issued notes held at fair value
  - ABS CDO super senior net exposure was £4,671m (30th June 2007: £7,432m). Exposures are stated net of writedowns and charges of £1,412m (30th June 2007: £56m) and hedges of £1,347m (30th June 2007: £348m).
  - Barclays Capital held other exposures impacted by the turbulence in credit markets, including: whole loans and other direct and indirect exposures to US sub-prime and Alt-A borrowers; exposures to monoline insurers; and commercial mortgage backed securities. the net losses in 2007 from these exposures were £823m.
  - At 31st December 2007, drawn leveraged finance positions were £7,368m (30th June 2007: £7,317m). The positions were stated net of fees of £130m and impairment of £58m driven by widening of corporate credit spreads.
  - At 31st December 2007, Barclays Capital had issued notes held at fair value of £57.2bn (30th June 2007: £44.6bn). The general widening of credit spreads affected the carrying value of these notes and as a result revaluation gains of £658m were recognised in trading income.
- Appropriate and conservative valuation principles were used to assess the write-downs, but additional losses could arise if markets deteriorate further.

Net exposure to super senior and other sub-prime has been significantly reduced since June 2007. Alt A and Commercial mortgage exposures are below their October 2007 peak.

£m	Deal size	Subprime Assets	Jun 07	Oct 07	Dec 07	Jan 08
ABS CDO Super Senior						
MTM	2,640	2,257	2,071	1,049	1,087	984
Non MTM	4,693	2,702	4,080	3,663	3,782	3,762
High Grade	7,332	4,960	6,151	4,712	4,869	4,745
MTM	1,634	1,509	1,038	598	556	490
Non MTM	880	631	591	571	593	597
Mezzanine	2,514	2,139	1,629	1,169	1,149	1,087
Net Exposure Before Hedging	9,846	7,099	7,780	5,881	6,018	5,832
Hedges			(348)	(924)	(1,347)	(1,260)
Net ABS CDO Super Senior	**9,846**	**7,099**	**7,432**	**4,957**	**4,671**	**4,572**
Other US sub-prime						
Whole loans			2,900	3,037	3,205	3,215
Residuals			709	540	233	224
Other direct and indirect exposures			2,437	1,991	1,599	1,521
Other US sub-prime			**6,047**	**5,568**	**5,037**	**4,959**
Alt-A			**3,760**	**5,053**	**4,916**	**5,028**
Monoline Insurers			**140**	**250**	**1,335**	**1,755**
Commercial Mortgages			**8,282**	**13,751**	**12,399**	**12,439**
SIV-Lite Liquidity Facilities			**692**	**167**	**152**	**82**
Structured investment vehicles			**925**	**701**	**590**	**573**
Leveraged Finance			**7,317**	**7,310**	**7,368**	**7,368**

Significant market movements were experienced during October and November, and sub-prime markets have continued to decline



- Falling ABX prices reflect increasing delinquency rates and foreclosures in the U.S. as house prices have been falling on a national level.
- Rating agencies have been downgrading sub-prime securities in recent months which further depressed the indices prices; Moody's has also stated 2006 as the worst year for serious delinquencies since at least 2000. Accelerating delinquencies from 2007 bonds are likely to eclipse 2006.

Sub-Prime Delinquency Levels reached record levels in mid-2007 and look set to increase further and then remain high through 2008.

Sub-Prime and Alt-A Delinquency Rates



Source: Barclays Capital Research (MBA definition of default)

ARM Reset Schedule



Source: Goldman Sachs Research

- Sub-prime delinquency rates are at record levels as at the end of September 2007. Their turning point has not yet been established.
- Delinquency rates are expected to climb further. Interest rate increases on low-start sub-prime mortgages (ARMs) which are a key driver of delinquency do not peak until March 2008.
- ARM interest rate increases will continue through 2008.
- The model used to assess our ABS CDO writedowns took prevailing delinquency levels on <u>our</u> assets (c.19% for 60+ days down) and applied a "roll rate" analysis which forecast that 70-100% of 60 day+ delinquencies, plus 15% of 30 day delinquencies (currently c.10% of sub-prime loans) will default over the next 18 months .

Other Areas of Concern – Exposure to Monoline Insurers

Total Global Financing Limits	31-Oct-07 GBP Millions	31-Oct-07 USD Millions	10-Mar-08 GBP Millions	10-Mar-08 USD Millions
ACA CAPITAL HOLDINGS GROUP	11	22	-	-
AMBAC FINANCIAL GROUP	853	1,766	459	925
ASSURED GUARANTY GROUP	386	799	364	734
CIFG (part of Natixis Group)	186	385	162	326
FGIC GROUP	537	1,111	175	352
FSA (part of Dexia Group)	1,507	3,120	1,506	3,032
MBIA GROUP	868	1,796	781	1,574
RADIAN GROUP	40	83	-	-
SECURITY CAPITAL ASSURANCE GROUP	235	487	215	432
TOTAL	4,622	9,568	3,662	7,374
Primary Exposure (principally liquidity support to Triple A One Funding (MBIA) & MBIA revolver)	159	330	164	330
Primary Exposure (liquidity support to Sheffield Receivables Corporation on Wrapped Securitizations)	30	62	189	380
Derivatives Limits, principally related to Negative Basis Trade Portfolio	2,352	4,868	2,027	4,082
Inflation Linked Derivative Exposure Wrapped by FSA UK Ltd & MBIA Assurance SA	1,193	2,470	1,238	2,493
Headroom	888	1,838	44	89
TOTAL	4,622	9,568	3,662	7,374

- Total direct exposure to Monoline Financial Guaranty Insurers ("monolines") totals $7.3bn including uncommitted headroom of $0.1bn. This has reduced from $9.6bn (including $1.8bn headroom) as at the end of October 2007.
- $0.7bn of exposure is primary. $6.5bn is in the form of trading limits where exposure is calculated on a potential future exposure basis ("PFE")*. FSA, MBIA, Ambac and Assured Guaranty account for 85% of the total exposure.
- Of the $6.5bn the most significant element ($4.1bn) relates to a portfolio of bonds which are guaranteed by monolines and booked as CDS Protection Purchases .
- Limits to monolines not part of a wider group are currently suspended pending review once the current position stabilises and ratings are more certain.

** PFE is an estimate of the potential exposure that could arise to a 98% confidence interval based on the spreads and ratings of the underlying bonds.*

Other Areas of Concern – Exposure to Monoline Insurers (cont'd)

Negative Basis Book Notionals

Counterparty name used	CFRM Category	Current notional (£m)
MBIA	CRE Loans	219
	European CLO	678
	European Mezz ABS	1,361
	US CLO	1,386
	US CMBS	4,541
	US High-Grade ABS	1,870
	US Mezzanine ABS	1,026
MBIA Total		11,080
AMBAC	CDO^2 (ABS)	79
	European CLO	2,436
	Infrastructure	868
	US CLO	4,503
	US High-Grade ABS	949
AMBAC Total		8,835
FSA	Bank & Insurance TRUPs	95
	European CLO	216
	US CLO	5,915
FSA Total		6,227
ASSURED	Bank & Insurance TRUPs	95
	CRE Loans	100
	Euro REIT Trust Preferred and CMBS	1,398
	European CLO	2,178
	REIT Trust Preferred	221
	US CLO	2,028
ASSURED Total		6,020
FGIC	European CLO	802
	US CLO	3,004
	US Mezzanine ABS	155
FGIC Total		3,962
CIFG	Bank & Insurance TRUPs	147
	European CLO	2,247
	US CLO	770
CIFG Total		3,164
XLCA	Emerging Markets Gov and Corp	192
	European CLO	1,433
	US CLO	606
	US CMBS	620
	CDO^2	107
XLCA Total		2,958
TOTAL		42,245

Negative Basis Book MTM (GBP Millions)

	31-Dec-07	31-Jan-08	26-Feb-08
MBIA	718	1,026	1,086
AMBAC	235	313	328
Assured	109	138	144
FSA	106	136	179
FGIC	102	122	122
XL	66	81	115
CIFG	50	58	56
ACA	9	-	-
Totals	1,395	1,874	2,030
Reserves	(60)	(119)	(101)
Net Exposure	1,335	1,755	1,929

- The notional value of the underlying securities in the negative basis book is \$42.3bn. The total includes \$4bn of US High Grade and Mezz ABS CDOs guaranteed by MBIA, Ambac and FGIC.
- In order for a loss to occur in the negative basis book a default in both the underlying security and the monoline is required. The underlying bonds were all originally rated AAA. So far, \$1.9bn of these bonds have been downgraded from AAA.
- The nature of the policies supporting the negative basis book obligate the insurer to continue to make payments of principal and interest according to the original contract of any defaulted reference obligation – there is no MTM settlement of the obligation at default but a continuing pay as you go obligation from the financial guarantor. This protects the monolines from a liquidity crunch in the event of a high level of defaults in the securities they guarantee.

Leveraged Loan underwrites at 29 Feb 08 of £8.9bn were broadly in line with the £8.7bn presented to BRC in December 2007

BarCap Primary Leverage Exposure	US eq £ms	Asia eq £ms	E'pe eq £ms	Total eq £ms	As at 29 February 2008
Underwriting - committed positions	**£3,329**	**£83**	**£5,485**	**£8,896**	'Hung' and 'new' deals, split £7.5bn 'hung' and £1.4bn 'new'
Of which Junior Debt is :	*£1,007*	*£67*	*£1,508*	*£2,581*	Primary LevLoans relates to our exposure to the specific sponsor led LBO market. Top 3 'hung' positions are AA/Saga £2.5bn, Alltel £2.4bn and Alliance Boots £0.8bn
Junior Debt Underwrite Cap is:	£1,750	within E'pe	£2,000	£3,750	
Equity Bridge position:	*£0*	*£0*	*£2*	*£2*	
Equity Bridge Cap is:	£350	within E'pe	£350	£700	
Holds - existing portfolio	£392	£68	£491	£951	Existing portfolio is spread across 49 accounts globally with an average exposure per name of c.£20m
Holds - targeted in underwriting positions	£241	£63	£532	£836	
Total targeted holds	**£632**	**£132**	**£1,023**	**£1,787**	
Of which Junior Debt is :	*£25*	*£0*	*£23*	*£48*	
Total Primary LevLoan Exposure	£3,961	£215	£6,508	£10,684	Our 'hung' exposure ranks us 11th globally (Top 3: Citi £30bn, BoA £27bn and JPM £21bn - source Lehmans Global Equity Research)
CLO Warehouse Positions	£364	nil	£771	£1,136	Warehouse positions pending securitisation
Total Return Swaps (TRS)	£9,185	£206	£3,045	£12,436	We have indirect exposure to the leveraged market via our hedge fund counterparty TRS financing book where we have haircuts in place assessed at a level which is assumed to equate to a nil risk position
First Lien	*78%*	*100%*	*86%*	*82%*	
Haircut	*24%*	*25%*	*28%*	*25%*	
# of trades	*76*	*7*	*33*	*123*	
Loan Investment Vehicles (LIVs)	n/a	n/a	£1,493	£1,493	Ex Polypony facilities with similar structures to TRS market value trades. Actual loan advance is c.50% of par asset value c.£3.0bn given the level of credit enhancement available (updated end Feb)

Exposure quoted net of swaps, Business Bank facilties, CDS and sub participations
Exposure also excludes secondary /distressed trading inventory positions
TRS haircut includes counterparty CDS and cash deposit against market value trades

- Barclays currently has leveraged underwriting positions of £8.9bn (excluding sanctioned holds). The increase to the October position is due to new business flows and currency movements.
- A series of steps have been taken to manage our risk :
  - We are selling debt where reasonable prices can be achieved - e.g. Alliance Boots mezzanine was at 95
  - We are being highly selective towards new business opportunities (e.g. no 100% underwrites, reduced leverage, improved terms/pricing and effective covenant packages)
- We are in general comfortable with the credit quality of the assets and are therefore continuing to hold rather than sell them down. A writedown of £188m was taken during October (£58m after fees), to reflect market conditions.

CONFIDENTIAL

BarCap's residential real estate portfolio was stress tested earlier in the year as part of an exercise for the FSA

- These stress test results were part of an exercise prepared for the FSA in Jan/Feb 2008 and intended to reflect a 1 in 20 stress from the current position
- It therefore assumes significant deterioration of an already distressed market.
- The exposures (drawn amounts) used for this exercise do not include indirect exposures and so will not tie directly to December or January month-end balances.

£m	Drawn amount	Stressed Amt		Relative stress	Loss horizon
US Subprime, Alt A and ABS Super Senior					
MTM positions (ex cashflow Super Senior)	997	176		N/A	Weeks
Cashflow PV Super Senior Migrating to NAV valuation	2,002	634		N/A	6-24 months but instant per deal
Cashflow PV Super Senior with Increased Cumulative Loss	2,153	311		N/A	6-24 months
Total ABS CDO SS exposure	**5,152**	**1,121**			
Sub-prime Whole Loans	3,014	258		N/A	6-24 months
Sub-prime Post NIM Residuals	122	74		N/A	6-12 months
Sub-prime NIM	113	45		N/A	6-12 months
Total sub-prime	**3,249**	**377**			
Alt A Securities: Prime/Relo	420	25		N/A	Weeks
Alt A Securities: Alt-A/Option ARM	2,257	219		N/A	Weeks
Alt A Whole Loans	886	40		N/A	6-24 months
Alt A Residuals	26	9		N/A	6-12 months
Total Alt A	**3,589**	**293**			
European RMBS					
2a7 Backstop facilities	2,900	45	£382mm funded	1.60%	3-6 months
European RMBS Secondary Trading	2,500	33		1.30%	3-6 months
Liquidity Facilities	1,900		Nil drawn exposure		
Residual Loans	270				
For Securitisation (warehouses)	2,000	95		4.80%	6-12 months
Total	**9,570**	**173**			

Analysis continued overleaf……

BarCap's commercial real estate and leveraged loan portfolio was also stress tested earlier in the year as part of an exercise for the FSA

£m	Drawn amount	Stressed Amt		Relative stress		Loss horizon
Commercial Real Estate						
Securitisation UK & Europe	4,700	189		4% net of fees	5.3% gross of fees	3-6 months
Take and Hold US	2,750	392		14.20%		12-24 months
Secondary Trading UK & Europe	1,000	38		3.80%		0-3 months
Syndication US	3,800	150		3.90%		12-24 months
Securitisation US	310	2		6.40%	of un-hedged portion	12-24 months
Secondary Trading US	200	14		7%		10 days
Total MTM	**12,760**	**785**				
Take and Hold UK & Europe	2,300	16	quoted	1.00%		12-24 months
		49	unquoted	2.60%		12-24 months
Syndication UK & Europe	1,400	108		7.7% net of fees	8.5% gross of fees	6-18 months
Total accrual	**3,700**	**173**				
Global Leveraged Loans						
Hung underwrites	7,500	360		4.8% net of fees	6.5% gross of fees	12-24 months
New underwrites	1,100	20		1.7% net of fees	2.5% gross of fees	3-6 months
Take and hold portfolio	1,700	75		4.5% gross of fees		12-24 months
Leveraged loan LIV portfolio	1,300	2		0.15%		6-12 months
CLO warehouse	1,100	58		5.0% gross of fees		6-12 months
Total	**12,700**	**515**				
Total Return Swaps	13,800	20		0.15%		6-9 months

CONFIDENTIAL

BGI money funds comprise a small proportion of sub-prime and SIV-related ABCP; some funds have experienced NAV or ratings pressure and have received support from Barclays

UPDATE as of Mar 10th

Summary

- Poor market liquidity and price transparency of sub-prime and SIV-related assets has put downward pressure on valuation for Stable NAV cash funds ("money funds") which contain some (usually limited) exposures to these assets
- In the current climate US clients and media are focused on this issue and several competitors (Bank of America, Legg Mason, CSFB) have taken steps to prevent their funds from "breaking the buck".
- BGI has $252bn in money funds outstanding as at 4 March, with approx. $3.9bn in SIV-related ABCP paper that has not been brought on balance sheet by its bank sponsor (1.5%), $3.4bn in sub-prime assets (1.4%), and $1.8bn in Alt-A assets (0.7%) spread across a number of funds.
- Selected funds have experienced NAV and/or ratings pressure from defaulted or illiquid securities, and as such a series of support actions have been taken, incl. asset purchases from funds, credit support agreements, and investor payments. These actions are set out in the table.
- We are currently considering whether additional credit support of ~$150-250m for selected funds is needed

Support Actions to Date

Support Type	Description or Notional Size	Fund Type
Asset Purchases	$225m of ABCP – KKR ($0 remaining on balance sheet)	US 2a-7
	$225m of SIV – Cheyne ($125m remaining on balance sheet)	US 2a-7
	$975m of SIV – Whistlejacket ($975m remaining on balance sheet)	US 2a-7, UK First
Support Agreements	$359.1m	US CTF & Sweep
	$37.4m	UK Liability Driven Investment Products
	$10.0m	Delaware Cash Advantage (Enhanced Cash)
	$5.3m	UK Plus
Investor Payments	$3.6m	Cayman Cash Advantage (Enhanced Cash)